Highlights from the 22nd European Neuroendocrine Tumor Society (ENETS) Conference

The 22nd Annual European Neuroendocrine Tumor Society (ENETS) Conference took place from March 5–7 in Krakow, Poland.

Founded in 2004, ENETS is the leading and longest-established society dedicated to improving the diagnosis and treatment of neuroendocrine tumors (NETs). With over 1,500 members across disciplines such as oncology, endocrinology, gastroenterology, nuclear medicine, pathology, radiology, surgery, and basic/translational science, ENETS continues to drive progress in NET care.

This year’s congress brought together 1,000+ registered participants, showcasing potentially practice-changing clinical data. Highlights included ITM’s late-breaking abstracts, featuring phase III results from the COMPETE trial and an update on the OCLURANDOM trial.

On the last day of the conference, the traditional INCA/ENETS Joint Symposium took place, highlighting the importance of collaboration between NET researchers and patient advocates to improve patient-centered care for neuroendocrine neoplasms (NENs). Moderated by Stephanie Alband (INCA) and Rocio Garcia-Carbonero (ENETS), the session addressed key topics such as integrating patient insights into research, fostering strong partnerships between patients and researchers, aligning priorities, and advancing global NEN research. The wrap-up emphasized the need for early patient involvement and diverse, patient-centered approaches to minimize participation burdens and maximize the impact of research.

During the conference, Philippe Ruszniewski was awarded the ENETS Life Achievement Award. This prestigious honor recognizes distinguished scientists who have made significant contributions to the field of neuroendocrine tumors through research or clinical practice.

Our team at OncoDaily has selected several highlights from social media that captured the energy and innovation of ENETS 2025.

Louis de Mestier:

“Immunotherapy has a place in pancreatic neuroendocrine tumors!

Alkylating-based chemotherapy is an effective treatment in patients with pancreatic neuroendocrine tumors, but it can promote grade progression and the acquisition of a hypermutator phenotype, which can impair prognosis.

Although immunotherapy is generally not a good option in advanced PanNETs, we report for the first time its efficacy in patients pretreated by alkylating agents and whose disease have acquired high TMB and MisMatchRepair alterations.

Consider systematic re-biopsy in these patients, to look for molecular targets, and to identify the best candidates for immunotherapy!

To be confirmed prospectively…

I hope that these results will motivate the pharmaceutical industry to get involved in this enthusiastic perspective… even if it has been considered too “niche” to deserve its interest so far…

I was very happy and proud to present our results today during ENETS 2025 and I thank all my coauthors for this very exciting collaboration.”

Mariano Dioca:

“Two important trials presented at ENETS 2025 that may be guiding future decisions in 1st and 2nd line in neuroendocrine tumors, higher responses and better PFS for PRRT, but can we expand access to PRRT and make it more dynamic for our patients?”

Stefano Partelli:

“Cristina Scielzo from Ospedale San Raffaele presenting at ENETS 2025 on 3D bioprinting reconstruction of the tumor microenvironment in vitro.

Innovative models to study pancreatic NET biology and therapy response.”

Udhayvir Grewal:

“Great talk as always on updates in well-differentiated NETs by one and only Thor Halfdanarson at the joint NANETS-ENETS session this AM. Lots of progress made and more ongoing…evolving role of personalized therapies? Should we sequence tumors more?

Many burning questions.”

Angela Lamarca:

Oral presentation at ENETS 2025 by Dr. Baudin on randomized phase II OCLURANDOM trial in PanNETs.

177LuDOTAOctreotate vs Sunitinib

• PFS data favours PRRT (ESMO),
• ORR 63 % vs 30% (similar DOR),
• Patients reported less toxicity with PRRT,
• Long-term toxicity to be monitored.”

Thor Halfdanarson:

“Serotonin as a villain and a target in small bowel NETs.

An excellent miniseries of talks at ENETS 2025.

Fibrosis including mesenteric fibrosis is a fascinating and challenging complication of sbNETs.

Po Hien Ear is excellent as always!”

Rachel Riechelmann:

“Dose-reduced cancer therapies often keep efficacy while avoiding major toxicity (+cost).

Our collaborative study in GEP NETs shows:

• Lenvatinib 10mg/day mPFS 14 months
•  RR: 32%

Similar to 24mg/day in the TALENT trial by Jaume Capdevila. ”

Udhayvir Grewal:

“A masterful talk on all things NECs by Jaume Capdevila at the joint NANETS-ENETS session at ENETS 2025 this morning. NECs remain an area of huge unmet need. Lots of questions on tailored strategies remain.

Newer targets with promising therapies- trials ongoing/planned.

Biomarkers? Tissue agnostic approach?”

Julie Hallet:

“Because you can resect does not mean you should.

Not all NETs are the same.

Stefano Partelli is introducing biological unresectability for PNETs at ENETS 2025, identifying futile surgery and when pre-operative therapy will help.

We have drug options – let’s figure out how to combine them with surgery!”

Louis de Mestier:

“Congratulations to Dr. Thomas Hunaut who perfectly presented today at ENETS 2025 the clinical results of the “Familial midgut neuroendocrine tumors – Familial Carcinoid Tumors” nationwide cohort from the Endocrine Tumor Study Group!

A very large study comparing 96 “familial” patients with 2430 “sporadic” cases from the GTE database.

• Familial small-intestine NETs do exist
• 3% to 5% of all small-intestine NETs
• At diagnosis, patients are younger, have more frequent multiple NETs (63% vs. 17%), and more frequent carcinoid syndrome (32% vs. 19%)
• Possible pejorative prognostic impact? Multiple NETs seem to matter

Underlying genomic alterations – undiscovered to date – are currently under investigation by Agathe Hercent, Thomas Hunaut, Eric Pasmant, Djihad Hadjadj, Thomas FERON, Jerome Cros, and Guillaume Cadiot.

What about familial screening? Nothing very clear at the moment…”

Francesca Spada:

“Great talking about non-SSA systemic therapies in bronchial carcinoids with carcinoid syndrome at an amazing and stimulating ENETS 2025 in Krakow.

Thanks to ENETS, Simona Glasberg for the case discussion, and the scientific program committee for the opportunity to improve and share knowledge in NENs once again.”

Angela Lamarca:

“Presented at ENETS 2025 by Nicola Fazio.

The SARC Europe initiative, supported by ENETS, will look into radioligand therapy in Europe and how to make this a reality equally accessible to all.

Lots of data support PRRT, let’s now deliver on getting it to our patients.”

The 23rd Annual ENETS Conference is scheduled to take place from March 4 to 6, 2026, in Krakow, Poland.

For more, stay tuned with OncoDaily.